Histone deacetylase inhibitor for NUT midline carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• NUT Midline carcinoma (NMC) is a rare, aggressive, and fatal poorly differentiated carcinoma.
• NMC is defined by a specific chromosomal rearrangement involving the nuclear protein of the testis (NUT) gene.
• Current treatment strategies for NMC often fail to achieve durable responses.

Observation:

• A case study of a 17-year-old female with widely metastatic NMC is presented.
• The patient initially responded to combination chemotherapy but experienced rapid disease progression.
• Treatment with vorinostat, a histone deacetylase inhibitor (HDACi), led to an objective response.

Findings:

• Histone deacetylase inhibitors (HDACi) demonstrate potential activity in treating advanced NUT Midline carcinoma.
• Despite an objective response to vorinostat, the patient's survival was less than one year from diagnosis.

Implications:

• The findings suggest that HDAC inhibitors may offer a therapeutic avenue for NMC.
• Further research is needed to explore the efficacy and optimal use of HDAC inhibitors in NMC treatment.
• This case highlights the urgent need for novel therapeutic strategies for this invariably fatal cancer.